Compare DAIO & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAIO | GLTO |
|---|---|---|
| Founded | 1969 | 2011 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4M | 23.7M |
| IPO Year | N/A | 2020 |
| Metric | DAIO | GLTO |
|---|---|---|
| Price | $3.06 | $30.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.22 | ★ $36.00 |
| AVG Volume (30 Days) | 26.6K | ★ 207.8K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,701,000.00 | N/A |
| Revenue This Year | $9.14 | N/A |
| Revenue Next Year | $2.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.88 | $2.01 |
| 52 Week High | $3.57 | $33.60 |
| Indicator | DAIO | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 70.94 |
| Support Level | $2.86 | $25.60 |
| Resistance Level | $3.20 | $32.20 |
| Average True Range (ATR) | 0.14 | 3.02 |
| MACD | 0.05 | 0.76 |
| Stochastic Oscillator | 74.56 | 92.21 |
Data I/O Corp is a provider of programming, security deployment, security provisioning, and associated Intellectual Property protection and management solutions used in electronics manufacturing with flash memory, microcontrollers, and flash memory-based intelligent devices as well as secure element devices, authentication devices, and secure microcontrollers. It is engaged in focused on the design, manufacturing and sale of programming systems used by designers and manufacturers of electronic products. It has its geographic presence in the United States, Europe, and Asia and others. The company derives the majority of its revenue from Asia and others.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.